Cipla Q2 results: Net profit rises nearly 4% YoY to ₹1,351 crore; revenue up 8%

In the corresponding period of the last fiscal year, it had clocked a profit of ₹1,302.53 crore, the firm said in a regulatory filing.

Cipla witnessed a 7.63% YoY surge in its total revenue from operations to ₹7,589.44 crore during the quarter under review, compared to ₹7,051.02 crore in the September quarter of the 2024-25 fiscal year (Q2FY25).

On a geographical basis, the drug manufacturer derived 41% of its revenue from India, 27% from North America, 16% from Africa, 13% from emerging markets and Europe, 2% from API, and 1% from others.

At an operational level, its EBITDA (earnings before interest, tax, depreciation, and amortisation), also known as operating profit, stood at ₹1,895 crore in the second quarter of FY26, marking a 0.5% YoY jump from ₹1,886 crore in the year-ago period.

However, its EBITDA margin contracted by 170 basis points (bps) to 25% during the quarter, as against 26.7% in the second quarter of the previous fiscal year.

CEO to step down

The company also announced that its Managing Director & Global Chief Executive Officer, Umang Vohra, will step down upon completion of his current term on March 31. 2026. Furthermore, he expressed his intention not to seek re-appointment as the MD and global CEO of Cipla.

Furthermore, as a part of the firm’s structured succession plan, Achin Gupta, who is currently the Global Chief Operating Officer, has been elevated and appointed as the MD and Global CEO, with effect from 1st April, 2026, for a term of five years.

What the management said

Commenting on the earnings, Umang Vohra, MD and Global CEO of Cipla Ltd, said: “I am pleased to share that we continue to make considerable progress across our focused markets. In Q2FY26, we delivered our highest-ever quarterly revenue of ₹7,589 crore, with a robust EBITDA margin of 25%. What makes this performance commendable is the breadth and balance of our growth, driven by contributions across all our focused markets.”

“Our One-India business grew at 7% YoY. Key therapies in the Branded Prescription business continued to deliver strong market growth, and with the launch of Yurpeak (Tirzepatide), we mark a pivotal step into obesity care through our strategic partnership with Eli Lilly. Trade Generics recorded a double-digit growth, and Anchor brands of Consumer Health Business maintained a leadership position,” Vohra added.

He said that with a positive traction in the firm’s differentiated assets, the US business posted a revenue of $233 million during the quarter. In Q3 FY26, gRevlimid is projected to have a small contribution to the US revenue, with the base business expected to continue growing. Upcoming launches, subject to USFDA approvals, are expected to alleviate gRevlimid revenue decline over the next four quarters, though there may be a timing gap before the full benefit is realised.

“In One Africa, we achieved a healthy growth of 5% YoY in USD terms. Emerging Markets and Europe delivered a solid revenue growth of 15% YoY in USD terms on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline as well as focusing on resolutions on the regulatory front,” Vohra stated.

Shares of Cipla declined as much as 4.88% to an intra-day low of ₹1,504 apiece on the National Stock Exchange (NSE) after the results were declared.

As of 2:04 pm, the stock was trading 2.73% lower at ₹1,538 per equity share. The drugmaker has a total market of ₹1.28 lakh crore, as of October 30, 2025, according to data on the NSE.